Dapagliflozin Management in AKI with CKD
Hold dapagliflozin during acute kidney injury, but once the patient is stabilized and the acute illness has resolved, restart it promptly—even if eGFR remains below baseline—as continuation provides superior long-term kidney and cardiovascular protection. 1
Clinical Approach to SGLT2i During AKI
When to Hold Dapagliflozin
The KDIGO 2024 guidelines explicitly state it is reasonable to withhold SGLT2i during times of prolonged fasting, surgery, or critical medical illness when patients may be at greater risk for ketosis 1. The FDA label reinforces this, recommending withholding dapagliflozin for at least 3 days prior to major surgery or procedures with prolonged fasting 2. This same principle applies to AKI, which represents a critical medical illness.
Specific triggers to hold:
- Volume depletion or hypotension
- Prolonged fasting or inability to maintain oral intake
- Critical illness requiring ICU-level care
- Sepsis or other acute systemic illness
- Perioperative period
When to Restart After AKI
The key principle: Once initiated, continue SGLT2i even if eGFR falls below 20 mL/min/1.73 m², unless not tolerated or kidney replacement therapy is initiated 1. This is a critical practice point that directly addresses your question.
Criteria for re-initiation after AKI:
- Resolution of acute illness (no longer critically ill, sepsis resolved, hemodynamically stable)
- Adequate volume status (not hypovolemic, blood pressure stable)
- Able to maintain oral intake (not NPO, not prolonged fasting)
- No active ketosis risk (not in DKA, adequate nutrition)
Do NOT wait for:
- eGFR to return to baseline (the reversible eGFR dip is expected and not harmful) 1, 3
- Complete resolution of creatinine elevation
- eGFR to rise above any specific threshold
The Evidence Supporting Early Continuation
The DAPA-CKD trial data show that patients who experienced acute eGFR reductions >10% after starting dapagliflozin actually had better long-term kidney outcomes with slower eGFR decline (-1.58 mL/min/1.73 m²/year) compared to those without acute drops 3. This acute dip is hemodynamic, reversible, and not associated with increased adverse events or CKD progression.
Even more compelling, in patients with heart failure who experienced deterioration of eGFR to <25 mL/min/1.73 m² during follow-up, continuing dapagliflozin reduced cardiovascular outcomes (HR 0.53) with no excess safety signals 4. The benefit-to-risk ratio favored continuation.
Recent 2026 data from cardiac surgery patients showed that dapagliflozin initiated just 1 day before surgery and continued postoperatively reduced AKI incidence by 46% (28% vs 52%, RR 0.54) 5. This suggests SGLT2i may actually be protective against AKI rather than causative.
Starting vs. Continuing: Different Scenarios
If patient was already on dapagliflozin before AKI:
- Hold during acute illness
- Restart as soon as clinically stable (typically within days to 1-2 weeks)
- Do not discontinue permanently due to AKI episode
If considering new initiation in CKD patient with recent AKI:
- Wait until acute illness fully resolved and patient stable
- Once stable, initiate according to standard KDIGO criteria (eGFR ≥20 mL/min/1.73 m² with appropriate indications) 1
- The presence of recent AKI (now resolved) is not a contraindication
Monitoring After Restart
Check within 2-4 weeks:
- Serum creatinine/eGFR (expect possible 10-15% acute dip, which is acceptable) 1
- Volume status and blood pressure
- Electrolytes (particularly if on RASi)
Do NOT discontinue if:
- eGFR drops acutely by 10-15% (this is expected hemodynamic effect) 3
- eGFR remains below initiation threshold (continuation is appropriate even <20 mL/min/1.73 m²) 1
DO discontinue only if:
- Symptomatic hypotension despite volume optimization
- Recurrent ketosis
- Intolerance (genital infections, UTIs)
- Initiation of kidney replacement therapy 1
Common Pitfalls to Avoid
- Permanently discontinuing SGLT2i after AKI episode - This deprives patients of proven mortality and kidney protection
- Waiting for eGFR to "recover" to baseline - The acute dip is protective, not harmful
- Confusing acute hemodynamic eGFR changes with true kidney injury - SGLT2i cause functional GFR reduction that preserves long-term kidney function
- Holding indefinitely in "sick day" scenarios - Resume promptly once acute illness resolves
The Bottom Line Algorithm
AKI develops in CKD patient on dapagliflozin:
↓
HOLD during acute illness
↓
Acute illness resolves + hemodynamically stable + adequate PO intake
↓
RESTART dapagliflozin (regardless of current eGFR)
↓
Monitor creatinine in 2-4 weeks
↓
Continue indefinitely unless intolerance or KRT initiatedThe evidence strongly supports aggressive continuation of SGLT2i therapy in CKD patients, even through episodes of kidney function deterioration, as the long-term benefits on mortality, cardiovascular outcomes, and kidney preservation far outweigh theoretical acute risks 1, 4, 3.